Table Graph
      published meta-analysis   sensitivity analysis   studies

doxycycline in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsHashim A, 2020 0.48 [0.11; 1.99] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] 0.39[0.11; 1.42]Hashim A, 2020, NCT04523831 (Mahmud), 202020%503moderatenot evaluable clinical deteriorationdetailed resultsHashim A, 2020 0.40 [0.10; 1.63] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] 0.44[0.24; 0.78]Hashim A, 2020, NCT04523831 (Mahmud), 202020%503moderatenot evaluable clinical improvementdetailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable clinical improvement (7-day)detailed resultsNCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] 1.93[1.27; 2.93]NCT04523831 (Mahmud), 202010%363NAnot evaluable clinical improvement (time to event analysis only)detailed resultsNCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] 1.89[1.06; 3.38]NCT04523831 (Mahmud), 202010%400NAnot evaluable serious adverse eventsdetailed resultsNCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] 3.97[0.18; 88.58]NCT04523831 (Mahmud), 202010%363NAnot evaluable adverse eventsdetailed resultsNCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] 18.57[1.07; 322.77]NCT04523831 (Mahmud), 202010%363NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-04-16 21:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 754 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons